Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of extended vs standard interval dose of Ocrelizumab therapy on Multiple sclerosis patients during Covid-2019 pandemic in Italy

Next Previous
Trial Profile

Comparison of extended vs standard interval dose of Ocrelizumab therapy on Multiple sclerosis patients during Covid-2019 pandemic in Italy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 20 Aug 2022 New trial record
  • 28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top